Molo (GSP 301) fixed-dose combination nasal spray
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Molo (GSP 301) fixed-dose combination nasal spray, covering 2018-06-20 to 2018-06-20. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR) [Phase 2]